公开(公告)号：US10028985B2

公开(公告)日：2018-07-24

申请号：US15101182

申请日：2014-12-03

申请人： Xiu-Min Li ,  Danna Chung ,  Nan Yang

发明人： Xiu-Min Li ,  Danna Chung ,  Nan Yang

IPC分类号： A61K36/00 ,  A61K36/074 ,  A61K36/752 ,  A61K36/481 ,  A61K36/62 ,  A61K36/718 ,  A61K36/732

摘要： The present invention relates to formulations made up from extracts from Ganoderma lucidum, rhizome of Coptis chinensis, Radix astragali, Nelumbo nucifera Gaertn, Chaenomeles speciosa, and Fructus Aurantii. Pursuant to the invention, the formulations are used to treat obesity and the biological sequelae of obesity including cholesterol levels and glucose levels. While not limited to any particular mechanism of action the formulations may assert their effects by altering gene expression, in particular, the expression of PPARγ, FABP4, CPT1, UCP2, and AMPK.

公开(公告)号：US07854935B2

公开(公告)日：2010-12-21

申请号：US10592912

申请日：2005-03-14

申请人： Xiu-Min Li ,  Hugh A. Sampson ,  Ming-Chun Weng

发明人： Xiu-Min Li ,  Hugh A. Sampson ,  Ming-Chun Weng

IPC分类号： A61K36/06 ,  A61K9/00 ,  A61K47/00 ,  A61K36/00

CPC分类号： A61K45/06 ,  A61K36/074 ,  A61K36/484 ,  A61K36/489 ,  A61K2300/00

摘要： The present invention provides herbal formulas, and compositions thereof, that can treat or reduce the severity, intensity, or duration of asthma and asthma-related symptoms. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutically acceptable carriers or excipients, and may be administered prior to, during, or after the development of asthmatic symptoms in a patient in need thereof.

摘要翻译： 本发明提供可治疗或降低哮喘和哮喘相关症状的严重性，强度或持续时间的草药配方及其组合物。 组合物可以任选地包括一种或多种佐剂，细胞因子，包封材料或药学上可接受的载体或赋形剂，并且可以在有需要的患者中发展哮喘症状之前，期间或之后施用。

公开(公告)号：US10406191B2

公开(公告)日：2019-09-10

申请号：US14762416

申请日：2014-01-21

申请人： Xiu-Min Li ,  Hugh A. Sampson ,  Nan Yang ,  Kamal Srivastava ,  Charles Emala

发明人： Xiu-Min Li ,  Hugh A. Sampson ,  Nan Yang ,  Kamal Srivastava ,  Charles Emala

IPC分类号： A61K36/489 ,  A61K31/4375 ,  A61K31/7048 ,  A61K31/352 ,  A61K31/439

摘要： The present invention relates to extracts of Sophora Flavescens, and compounds isolated therefrom for use in modulating airway smooth muscle contractility. Methods of creating enriched extracts of Sophora Flavescens are disclosed, as are specific compounds isolated therefrom. Methods for the treatment of disorders involving airway smooth muscle, such as asthma, using the compounds and extracts described herein are also disclosed.

公开(公告)号：US20180044384A1

公开(公告)日：2018-02-15

申请号：US15436204

申请日：2017-02-17

申请人： Xiu-Min LI ,  Zhenwen Zhou ,  Zhigang LIU ,  Ying SONG

发明人： Xiu-Min LI ,  Zhenwen Zhou ,  Zhigang LIU ,  Ying SONG

IPC分类号： C07K14/28 ,  C12N15/70 ,  C12R1/63 ,  C12N1/20

CPC分类号： C07K14/28 ,  A61K35/742 ,  A61K39/07 ,  A61K39/35 ,  A61K39/39 ,  A61K2039/523 ,  A61K2039/542 ,  A61K2039/55 ,  A61K2039/55544 ,  A61K2039/577 ,  A61K2039/6037 ,  C07K14/415 ,  C12N1/20 ,  C12N3/00 ,  C12N15/70 ,  C12R1/63

摘要： The present disclosure provides compositions comprising recombinant bacterial spores. The present disclosure is also directed to vaccine based compositions, which include recombinant bacterial spores that express CTB and a peanut protein(s) on their surfaces. This disclosure also provides methods for administering these compositions as a treatment or prevention of peanut allergy.

公开(公告)号：US20160296573A1

公开(公告)日：2016-10-13

申请号：US15101182

申请日：2014-12-03

申请人： Xiu-min LI ,  Danna CHUNG ,  Nan YANG

发明人： Xiu-Min LI ,  Danna CHUNG ,  Nan YANG

IPC分类号： A61K36/074 ,  A61K36/752 ,  A61K36/62 ,  A61K36/732 ,  A61K36/718 ,  A61K36/481

CPC分类号： A61K36/074 ,  A61K36/481 ,  A61K36/62 ,  A61K36/718 ,  A61K36/732 ,  A61K36/752 ,  A61K2236/00 ,  A61K2300/00

摘要： The present invention relates to formulations made up from extracts from Ganoderma lucidum, rhizome of Coptis chinensis, Radix astragali, Nelumbo nucifera Gaertn, Chaenomeles speciosa, and Fructus Aurantii. Pursuant to the invention, the formulations are used to treat obesity and the biological sequelae of obesity including cholesterol levels and glucose levels. While not limited to any particular mechanism of action the formulations may assert their effects by altering gene expression, in particular, the expression of PPARγ, FABP4, CPT1, UCP2, and AMPK.

摘要翻译： 本发明涉及由灵芝的提取物，黄连，黄芪，木犀，木槿和枸杞提取物制成的制剂。 根据本发明，该制剂用于治疗肥胖症和肥胖的生物后遗症，包括胆固醇水平和葡萄糖水平。 虽然不限于任何特定的作用机制，但制剂可通过改变基因表达，特别是PPARγ，FABP4，CPT1，UCP2和AMPK的表达来断定其作用。

公开(公告)号：US20160175291A1

公开(公告)日：2016-06-23

申请号：US14857772

申请日：2015-09-17

申请人： Xiu-Min Li ,  Nan Yang ,  Chaoyi Mao ,  Ying Song

发明人： Xiu-Min Li ,  Nan Yang ,  Chaoyi Mao ,  Ying Song

IPC分类号： A61K31/4375 ,  A61K31/122 ,  A61K31/366

CPC分类号： A61K31/122 ,  A61K31/12 ,  A61K31/35 ,  A61K31/366 ,  A61K31/4745 ,  A61K31/475

摘要： The present invention relates to compounds and formulations derived from traditional Chinese medicine for use for the treatment and/or mediation of food allergies, in particular peanut allergies in humans by altering the activity and/or production of IgE.

摘要翻译： 本发明涉及通过改变IgE的活性和/或产生来用于治疗和/或调解食物过敏症，特别是人体花生过敏的中药的化合物和制剂。

公开(公告)号：US20150359834A1

公开(公告)日：2015-12-17

申请号：US14762416

申请日：2014-01-21

申请人： Xiu-Min LI ,  Sampson HUGH ,  Nan YANG ,  Kamal SRIVASTAVA ,  Charles EMALA

发明人： Xiu-Min Li ,  Sampson Hugh ,  Nan Yang ,  Kamal Srivastava ,  Charles Emala

IPC分类号： A61K36/489 ,  A61K31/4375 ,  A61K31/439 ,  A61K31/352 ,  A61K31/7048

CPC分类号： A61K36/489 ,  A61K31/352 ,  A61K31/4375 ,  A61K31/439 ,  A61K31/7048

摘要： The present invention relates to extracts of Sophora Flavascens, and compounds isolated therefrom for use in modulating airway smooth muscle contractility. Methods of creating enriched extracts of Sophora Flavascens are disclosed, as are specific compounds isolated therefrom. Methods for the treatment of disorders involving airway smooth muscle, such as asthma, using the compounds and extracts described herein are also disclosed.

摘要翻译： 本发明涉及苦参皂甙提取物及其分离的化合物，用于调节气道平滑肌收缩力。 公开了生产Sophora Flavascens的富集提取物的方法，以及从其分离的特定化合物。 还公开了使用本文所述的化合物和提取物治疗涉及气道平滑肌（例如哮喘）的病症的方法。

公开(公告)号：US20100322923A1

公开(公告)日：2010-12-23

申请号：US12528215

申请日：2008-02-21

申请人： Rolf Seljelid ,  Xiu-Min Li

发明人： Rolf Seljelid ,  Xiu-Min Li

IPC分类号： A61K39/395 ,  A61K31/716 ,  A61P11/06

CPC分类号： A61K31/716

摘要： The invention relates to a glucan having a beta-(1,3)-backbone with one or more beta-(1,3)-side chains linked thereto for use in the treatment of asthma and related diseases of abnormal pulmonary function in an animal. Also described is a method of treating asthma and related diseases of abnormal pulmonary function in an animal comprising administering to said animal an effective amount of a glucan having a beta-(1,3)-backbone with one or more beta-(1,3)-side chains linked thereto.

摘要翻译： 本发明涉及具有β-（1,3） - 骨架与一个或多个与其连接的β-（1,3） - 侧链的葡聚糖，用于治疗哮喘和动物异常肺功能的相关疾病 。 还描述了一种治疗动物异常肺功能的哮喘和相关疾病的方法，包括向所述动物施用有效量的具有β-（1,3） - 腰骨的葡聚糖与一种或多种β-（1,3 ）链。

公开(公告)号：US6121247A

公开(公告)日：2000-09-19

申请号：US826050

申请日：1997-03-28

申请人： Shau-Ku Huang ,  Marsha Wills-Karp ,  Xiu-Min Li ,  Andrea Keane-Myers

发明人： Shau-Ku Huang ,  Marsha Wills-Karp ,  Xiu-Min Li ,  Andrea Keane-Myers

IPC分类号： A61K38/21 ,  A61K48/00 ,  C07K14/57 ,  C12N15/00

CPC分类号： A61K38/217 ,  C07K14/57 ,  A61K48/00

摘要： Administration of an expression gene construct for IFN-.gamma. to an affected organ is an effective means of reversing antigen-induced inflammation. Suitable allergic diseases for treatment include atopic asthma, rhinitis, and dermatitis.

摘要翻译： 将IFN-γ的表达基因构建体施用于受影响的器官是逆转抗原诱导的炎症的有效手段。 合适的治疗过敏性疾病包括特应性哮喘，鼻炎和皮炎。

公开(公告)号：US06630176B2

公开(公告)日：2003-10-07

申请号：US09800815

申请日：2001-03-07

申请人： Xiu-Min Li ,  Hugh A. Sampson

发明人： Xiu-Min Li ,  Hugh A. Sampson

IPC分类号： A61K3578

CPC分类号： A61K36/736 ,  A61K36/074 ,  A61K36/232 ,  A61K36/258 ,  A61K36/268 ,  A61K36/54 ,  A61K36/714 ,  A61K36/718 ,  A61K36/756 ,  A61K36/758 ,  A61K36/9068 ,  Y10S514/826 ,  A61K2300/00

摘要： The present invention provides herbal compositions that can prevent or reduce the severity, intensity, or duration of allergic and/or asthmatic symptoms and/or can prevent or delay the development of an allergic or asthmatic response to an antigen. The compositions may optionally include one or more adjuvants, cytokines, encapsulating materials, or pharmaceutical carriers or excipients, and may be administered prior to, during, or after the development of allergic or asthmatic symptoms in sensitized individuals. Alternatively or additionally, the compositions may be administered prior to sensitization to a particular antigen; preferably substantially concurrently with exposure to the antigen.

摘要翻译： 本发明提供可以预防或降低过敏和/或哮喘症状的严重性，强度或持续时间和/或可以预防或延缓对抗原的过敏性或哮喘反应的发展的草药组合物。 组合物可以任选地包括一种或多种佐剂，细胞因子，包封材料或药物载体或赋形剂，并且可以在致敏个体中过敏或哮喘症状发展之前，期间或之后施用。 或者或另外，可以在对特定抗原敏化之前施用组合物; 优选基本上同时暴露于抗原。